Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoRT-Lung: Toripalimab + RT vs Toripalimab + Chemo for Neoadjuvant NSCLC
NCT05798845Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Feb 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05798845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798845.